FY2029 Earnings Forecast for HRMY Issued By HC Wainwright

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Harmony Biosciences in a research note issued to investors on Thursday, January 16th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of $5.99 per share for the year. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.42 per share.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.15. The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 EPS.

Several other brokerages also recently commented on HRMY. Oppenheimer reiterated an “outperform” rating and set a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. Cantor Fitzgerald raised their price target on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Raymond James reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Finally, Mizuho lifted their target price on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $55.00.

Harmony Biosciences Trading Up 1.3 %

Shares of HRMY opened at $39.05 on Monday. The company’s fifty day simple moving average is $34.46 and its 200-day simple moving average is $34.96. The company has a market cap of $2.23 billion, a P/E ratio of 18.51, a P/E/G ratio of 0.49 and a beta of 0.78. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a twelve month low of $28.14 and a twelve month high of $41.61.

Insiders Place Their Bets

In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 30.80% of the company’s stock.

Hedge Funds Weigh In On Harmony Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its holdings in Harmony Biosciences by 56.7% during the second quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock worth $17,975,000 after buying an additional 215,700 shares during the period. Marshall Wace LLP raised its position in shares of Harmony Biosciences by 145.4% in the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock worth $9,220,000 after acquiring an additional 181,092 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Harmony Biosciences by 27.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after purchasing an additional 140,690 shares during the last quarter. HealthInvest Partners AB boosted its position in Harmony Biosciences by 335.2% during the third quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock valued at $6,075,000 after purchasing an additional 116,975 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Harmony Biosciences by 13.3% in the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock valued at $28,871,000 after purchasing an additional 112,197 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.